Cargando…
P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ENGAGER (TCE) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) AND CELMOD AGENTS IN MULTIPLE MYELOMA (MM) PRECLINICAL MODELS
Autores principales: | Paiva, Bruno, Gaffney, Bonny, Burnett, Kelven, Castiglioni, Paola, Angelo, Michael, Pierce, Daniel W., Boss, Isaac |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430652/ http://dx.doi.org/10.1097/01.HS9.0000970100.80546.2a |
Ejemplares similares
-
P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Boss, Isaac, et al.
Publicado: (2023) -
P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
por: Wong, Sandy W., et al.
Publicado: (2023) -
Errors in TCE analysis.
por: Boice, J D, et al.
Publicado: (2001) -
PPARα and Effects of TCE
por: Klaunig, James E., et al.
Publicado: (2007) -
Meta-analyses of TCE carcinogenicity.
por: Borak, J, et al.
Publicado: (2000)